Compare PHAT & JQC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHAT | JQC |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 894.0M | 753.9M |
| IPO Year | 2019 | N/A |
| Metric | PHAT | JQC |
|---|---|---|
| Price | $12.64 | $4.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $19.83 | N/A |
| AVG Volume (30 Days) | ★ 969.5K | 832.9K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.13% |
| EPS Growth | ★ 42.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $175,110,000.00 | N/A |
| Revenue This Year | $93.04 | N/A |
| Revenue Next Year | $58.91 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 216.93 | N/A |
| 52 Week Low | $2.21 | $4.62 |
| 52 Week High | $18.31 | $5.58 |
| Indicator | PHAT | JQC |
|---|---|---|
| Relative Strength Index (RSI) | 64.20 | 54.70 |
| Support Level | $12.31 | $4.65 |
| Resistance Level | $12.88 | $4.89 |
| Average True Range (ATR) | 0.64 | 0.08 |
| MACD | 0.27 | 0.02 |
| Stochastic Oscillator | 80.87 | 91.07 |
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.